NEW YORK (Reuters) – A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness.
The 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge erred in dismissing the case, in part for having applied an improper legal standard to Regeneron’s claims.
(Reporting by Jonathan Stempel in New York)
